T he etiology of ischemic cerebrovascular disease (CVD) is heterogeneous, but the contribution of genetic as well as environment factors has been proposed. Age, smoking, hypertension, and diabetes have been established as independent risk factors for ischemic CVD. [1] [2] [3] [4] Although no gene has been convincingly shown to be of importance for ischemic CVD, obvious candidate genes are those with an established or potential role in atherosclerosis. The relationship between hyperlipidemia and CVD is controversial. 5, 6 Disorders of lipid metabolism associated with high levels of LDL cholesterol or low levels of HDL cholesterol have been recently recognized as risk factors for atherosclerotic vascular disease. Lipoprotein lipase (LPL) plays a key role in lipoprotein metabolism as an enzyme that hydrolyzes triglycerides from VLDL and chylomicrons, as well as in the removal of lipoproteins from the circulation. [7] [8] [9] LPL influences the interaction of atherogenic lipoproteins with the cell surface and with receptors on the vascular wall. 10 -12 The human LPL gene is localized to chromosome 8p22, spanning approximately 30 kb and containing 10 exons. 13 Several DNA variants of the LPL gene have been found and reported to underlie changes in plasma lipoprotein levels and to be important cardiovascular risk factors. For example, HindIII polymorphism of intron 8 of this gene is associated with elevated triglyceride levels, 14, 15 low HDL cholesterol levels, 16, 17 and premature coronary artery disease (CAD). 15, 18 PvuII polymorphism of intron 6 is also associated with elevated triglyceride levels 14 and severity of CAD and with type II diabetes in CAD patients. 19 The Ser447Stop mutation has been identified just 635 bp downstream from the HindIII polymorphism. This mutation is a consequence of a C to G transversion at nucleotide 1595 in exon 9, which converts the serine 447 codon (TCA) to a premature termination codon (TGA). 20, 21 Recent studies have suggested that risk of CAD is decreased by Ser447Stop polymorphism, which underlies increased HDL cholesterol levels and decreased triglyceride levels, 22 suggesting that it is a beneficial genetic variant with respect to lipoprotein metabolism. 23 Thus, Ser447Stop polymorphism should have a protective effect against the development of atherosclerosis and subsequent CAD.
To our knowledge, no studies have previously examined the clinical significance of these polymorphisms in patients with ischemic CVD. In the present study we used restriction fragment length polymorphism (RFLP) analysis to investigate the importance of polymorphisms of the LPL gene as risk factors for ischemic CVD. We also examined the relationship between these polymorphisms and the clinical subtype of ischemic CVD and serum lipid levels.
Subjects and Methods

Subjects
The study population consisted of 177 patients with ischemic CVD who had been admitted to Juntendo University Hospital or Ebara Metropolitan Hospital and 177 control subjects. All subjects enrolled in the study were Japanese. Brain CT and/or brain MRI, B-mode carotid ultrasonography, and electrocardiography were performed in all patients. On the basis of the Classification of Cerebrovascular Disease III by the committee of the National Institute of Neurological Disorders and Stroke, 24 ischemic CVD patients were divided into 3 clinical subtypes: (1) cardioembolic infarction caused by nonvalvular atrial fibrillation, (2) atherothrombotic infarction, and (3) lacunar infarction. CVD patients with transient ischemic attack and cerebral hemorrhage were not included in this study. Patients with significant internal carotid artery stenosis (Ͼ70%) on B-mode carotid ultrasonography were included in the category of atherothrombotic infarction (nϭ30). All patients were investigated at least 2 months after the occurrence of stroke. Blood samples for genotyping were taken after determination of the clinical subtype of CVD, and the mean interval between the onset of CVD and genotyping was 1.6Ϯ0.8 months. The examiner who performed the genotyping was blinded to the clinical subtype of ischemic CVD. The control group was randomly selected from the inpatients of the hospitals and matched with CVD patients for age and sex. Control subjects had no symptoms or history of ischemic stroke, CAD, or peripheral atherosclerotic disease. Brain CT and/or MRI and B-mode carotid ultrasonography were not performed in all control subjects. Informed consent was obtained from all subjects after they received a full explanation of the study. The Ethics Committee of Juntendo University approved this study.
Hypertension was defined as systolic arterial blood pressure Ͼ140 mm Hg and/or diastolic pressure Ͼ90 mm Hg or as current treatment with antihypertensive drugs. Diabetes was defined by the diagnostic criteria of the World Health Organization or as current treatment for diabetes.
Determination of LPL Ser447Stop Polymorphism by RFLP
Oligonucleotides
Polymerase chain reaction (PCR)-RFLP was used to detect Ser447Stop polymorphism in exon 9 of the LPL gene, with the use of the primers described previously. 23 Two polymorphisms, identified by restriction enzyme cleavage with HindIII (intron 8) and PvuII (intron 6) of a PCR-amplified segment of the LPL gene, were studied according to the previously reported protocol. 18 The primer sets were as follows: Ser447Stop mutation: forward primer, 5Ј-CATCCATTTTCTTCCACAGGG-3Ј; reverse primer, 5Ј-AGTCTGGTGAGCATTCTGGGCTA-3Ј; HindIII RFLP: forward primer, 5Ј-GATGTCTACCTGGATAATCAAAG-3Ј; reverse primer, 5Ј-CTTCAGCTAGACATTGCTAGTGT-3Ј; PvuII RFLP: forward primer, 5Ј-ATCAGGCAATGCGTATGAGGTAA-3Ј; reverse primer, 5Ј-GAGACACAGATCTCTTAAGAC-3Ј.
Amplification of Genomic DNA
Each amplification reaction was performed with 250 ng of genomic DNA; 10 pmol of each primer; 2 L of 10ϫ buffer solution; 200 mol/L each of dATP, dCTP, dGTP, and dTTP; and 1 U of Taq polymerase in a total volume of 20 L. Amplification was performed in a Gene Amp PCR system 9700 (Perkin Elmer-Cetus). In the case of amplification of exon 9, initial denaturation at 94°C for 5 minutes was followed by 30 cycles of denaturation at 94°C for 1 minute, annealing at 57°C for 1 minute, and extension at 72°C for 1 minute, with final extension at 72°C for 10 minutes. For amplification of intron 8, initial denaturation at 94°C for 5 minutes was followed by 30 cycles of denaturation at 94°C for 1 minute, annealing at 57°C for 1 minute, and extension at 72°C for 1 minute, with final extension at 72°C for 10 minutes. For intron 6, initial denaturation at 94°C for 5 minutes was followed by 30 cycles of denaturation at 94°C for 1 minute, annealing at 57°C for 1 minute, and extension at 72°C for 1 minute, with final extension at 72°C for 10 minutes.
Digestion and Electrophoresis
The C-G mutation at the LPL Ser447stop polymorphism site creates a MnlI recognition site (New England Biolabs). The PCR product of 488 bp contains 2 MnlI restriction sites, of which 1 is polymorphic and reveals the Ser447Stop mutation. Digestion of the PCR product results in 3 fragments of 285, 246, and 203 bp, which were confirmed on 3% agarose gel. The products obtained by digestion with HindIII and PvuII were electrophoresed on 2% agarose gel. After HindIII digestion, the presence of the restriction site (HindIIIϩ) resulted in fragments of 140 and 210 bp, while the presence of the PvuII site (PvuIIϩ) yielded fragments of 222 and 209 bp.
Serum Lipid Measurements
Blood samples for the evaluation of lipid levels were obtained from subjects between 8 and 11 AM, after at least 12 hours of fasting, from a forearm vein after venous occlusion for few seconds in a sitting position. Serum levels of total cholesterol (TC), HDL cholesterol, and triglycerides were measured by standard enzymatic methods. LDL cholesterol levels were calculated with the Friedewald formula.
Statistical Analysis
Serum triglyceride values were log transformed to remove positive skewness before analysis. The Hardy-Weinberg equilibrium for the LPL genotype distribution was assessed by 2 analysis. Data on age and lipid levels were presented as meanϮSEM, and differences between groups were analyzed by the unpaired Student's t test. The frequencies of the alleles and the relations of genotype between the study groups were analyzed by constructing 2ϫ2 and 2ϫ3 contingency tables followed by 2 analysis. Odds ratios and 95% CIs for relative risk of CVD associated with LPL Ser447Stop GGϩCG genotypes were determined by Pearson's 2 test and multiple logistic regression analysis after adjustment for age, sex, hypertension, and diabetes. A P value Ͻ0.05 was considered significant. Statistical analysis was performed with StatView version 5.0 for the Macintosh computer (SAS Institute).
Results
The characteristics of the subjects are summarized in Table 1 . There were no significant differences in age and sex between CVD patients and controls. The risk factors examined (ie, hypertension and diabetes) were significantly more commonly seen in CVD patients than in controls. Serum cholesterol and triglyceride levels tended to be higher in patients than in controls. In addition, 57 of 177 patients (32.2%) had hyperlipidemia, and 31 (54.4%) of these patients had already been treated with hypolipidemic agents. However, only 11 (35.5%) of these 31 treated patients showed improvement of lipid levels at that time.
The genotype distribution and the allele frequency for LPL gene polymorphism are summarized in Table 2 . The observed frequencies of the 3 genotypes did not differ from the expected frequencies according to the Hardy-Weinberg equilibrium for both the control group ( 2 ϭ1.03, dfϭ2, Pϭ0.60) and CVD patients ( 2 ϭ3.33, dfϭ2, Pϭ0.19). The G allele frequencies of the Ser447Stop polymorphism in CVD patients and control subjects were 0.107 and 0.158, respectively. The prevalence of Ser447Stop showed a significant difference between CVD patients and control subjects. The distribution of polymorphisms in each group of CVD patients and control group is shown in Table 2 . No significant differences in the distribution of genotypes or alleles were observed between control subjects and patients with cardio- .174) . However, the G allele was significantly more frequent in control subjects than in patients with atherothrombotic infarction (0.158 versus 0.077; Pϭ0.017). In addition, we analyzed 30 patients with atherosclerotic disease of the internal carotid artery causing Ͼ70% stenosis on B-mode carotid ultrasonography. The frequency of the G allele was 0.033 in these patients, and analysis showed a lower G allele frequency in these patients than in control subjects (Pϭ0.01). The frequency of the H allele (HindIII polymorphism) in CVD patients (0.164) was significantly lower than that in the control subjects (0.234; Pϭ0.03). In contrast, the P allele frequency (PvuII polymorphism) was not different between CVD patients and control subjects.
The relationships between Ser447Stop mutation and serum lipid levels are shown in Table 3 . There were no significant differences in the serum levels of TC, triglycerides, HDL cholesterol, and LDL cholesterol between CC and CGϩGG genotypes. HindIII and PvuII alleles did not correlate significantly with plasma levels of TC, triglycerides, HDL cholesterol, or HDL cholesterol (data not shown).
The odds ratios of the CGϩGG genotype for atherothrombotic infarction between atherothrombotic infarction patients and control subjects were 0.45 (95% CI, 0.22 to 0.93; Pϭ0.031) and, after adjustment for conventional risk factors, 0.42 (95% CI, 0.18 to 0.99; Pϭ0.046). Linkage disequilibriums between the 3 polymorphisms of LPL were determined in normal subjects. HindIII and PvuII alleles were in strong linkage disequilibrium (Dϭ0.157, D/Dmaxϭ94%; PϽ0.001). A signif- 
Discussion
In this study the frequency of the G allele was significantly higher in control subjects than in patients with atherothrombotic infarction. With the use of meta-analyses, previous studies showed that the odds ratio for ischemic heart disease was 0.8 (95% CI, 0.7 to 1.0), indicating a cardioprotective effect of this LPL gene variant. 25, 26 As was previously reported for patients with myocardial infarction, mutation of the Ser447Stop seems to be associated with a reduced risk of atherothrombotic cerebral infarction. The present study also demonstrated that patients with carotid stenosis had a lower G allele frequency. Therefore, the Ser447Stop allele was associated with a decreased risk of atherosclerotic disease of the internal carotid artery. However, Sass et al 27 reported no difference in the carotid wall intima-media thickness between carriers and noncarriers of the Ser447Stop mutation among normal middle-aged individuals. The observed discrepancies between studies could be explained by differences in the age and background of examined subjects. Sass et al 27 recruited individuals aged 33 to 50 years who had no history of cardiovascular disease and were not on any antihypertensive or hypolipidemic agents, whereas our subjects were selected from CVD patients. It is possible that the effect of the LPL Ser447Stop polymorphism is age dependent and may be low at baseline in healthy young people. Finally, the differences in results may be due to differences in the genetic and environmental background, ie, Japanese versus European population. The effect of this gene may be modulated or stimulated by different factors, such as individual lifestyles.
In contrast to the patients with atherothrombotic infarction, the frequency of this mutation was not different among patients with lacunar infarction, cardioembolic infarction, and control subjects, indicating a lack of association between lacunar or cardioembolic infarction and this polymorphism. Lacunar infarction is caused by several distinct mechanisms, including lipohyalinosis, microatheroma, atherosclerosis, embolism, and hemodynamic hypoperfusion. 28 -30 Cardioembolic infarction is caused by embolism in patients with nonvalvular atrial fibrillation, and there is no distinct role for atherosclerotic mechanisms. Therefore, the relationship between atherothrombotic infarction and this polymorphism may be stronger than in other types of CVD. Our results indicate that the Ser447Stop mutation in atherothrombotic infarction may protect against the development of atherosclerosis.
Previous studies showed that the Ser447Stop mutation was associated with increased HDL cholesterol and decreased triglyceride levels. 22, 23 Plasma and vascular wall LPLs have different roles in atherosclerosis. Clee et al 31 demonstrated that increased plasma LPL activity alone, in the absence of an increase in vascular wall LPL, is associated with a reduced susceptibility to atherosclerosis. On the other hand, decreased plasma LPL activity is associated with high triglycerides and low HDL phenotype, which is often observed in patients with premature vascular disease. The Ser447Stop mutation is reported to be associated with higher plasma LPL activity. Kozaki et al 32 investigated the expression of C-terminal truncated LPLs by assessing their activity and mass in culture media and in cells. The level of LPL Ser447Stop mutant was approximately twice as high as that of normal LPL in the medium. Therefore, this mutation increases HDL cholesterol levels and decreases triglyceride levels. However, we did not find any relationship between Ser447Stop mutation and serum lipid levels. Several reasons may account for these conflicting results. All CVD patients in the present study were selected from patients who had been admitted to the hospital at least 2 months after the occurrence of stroke. Therefore, the bias between selection and the time point of lipid measurements after stroke onset cannot be ignored in the present study. Variations in lipid and lipoprotein levels and composition have been observed during the acute period after ischemic cerebrovascular events. 33, 34 Woo et al 33 compared the serum lipid profile within 48 hours of the onset of stroke and 3 months later. They found significantly lower TC and LDL cholesterol levels as well as a significantly higher triglyceride level at 3 months after stroke compared with the data obtained within 48 hours after the onset. In our study a number of CVD patients had already been treated with hypolipidemic drugs, and some of them did not show any improvement in lipid levels. Therefore, it is likely that the difference in the timing of lipid measurement and treatment with lipid-lowering drugs could underestimate the correlation between this mutation and serum lipid levels.
The present study demonstrated that HindIII polymorphism is associated with increased risk of atherothrombotic infarction. Chen et al 35 reported that carotid artery atherosclerosis correlates significantly with the HindIII polymorphism in white male subjects. Likewise, Thorn et al 15 found that white patients with severe coronary atherosclerosis had a higher frequency of the Hϩ allele than healthy controls and suggested that HindIII polymorphism of LPL influences atherosclerotic disease. Both HindIII and PvuII polymorphism have been found in all racial groups, but Chamberlain et al 14 indicated that there were differences in the frequencies of both the HindIII and the PvuII alleles between whites and Japanese. The frequencies of HindIII and PvuII allele detected in the present study were similar to those described in healthy Japanese populations. The frequency of the G allele of LPL Ser447Stop polymorphism was similar to that reported in other countries. 18, 22, 23, 27 In fact, Murano et al 36 suggested that the Ser447Stop mutation might be distributed worldwide. In some studies, 14,17-19 a strong linkage disequi- librium among the 3 polymorphisms of LPL was found. Our data also show that the Ser447Stop mutation is in significant linkage disequilibrium with HindIII and PvuII.
In addition to the Ser447Stop mutation, other studies have investigated the association between other LPL mutations and atherosclerosis or ischemic CVD. [37] [38] [39] Asn291Ser polymorphism of the LPL gene is associated with reduced HDL cholesterol levels and premature atherosclerosis. 37 Only 2 studies have evaluated the relationship between other LPL gene mutations and ischemic CVD. Huang et al 38 reported that Asn291Ser polymorphism of LPL, similar to HindIII and PvuII polymorphism, did not significantly contribute to the risk of ischemic stroke. Wittrup et al 39 showed that Asn291Ser polymorphism was not associated with nonfatal ischemic CVD in men but was possibly associated with a 2-fold increased risk in women. However, they did not analyze the associations between the clinical subtypes of ischemic CVD and control subjects. To our knowledge, our study provides the first evidence of the relationship between clinical subtypes of ischemic CVD and the Ser447Stop polymorphism of LPL gene related to lipid metabolism.
In conclusion, G allele of Ser447Stop polymorphism is significantly less frequent in patients with ischemic CVD than in control subjects. Moreover, HindIII polymorphism is associated with increased risk of atherothrombotic infarction. The Ser447Stop mutation is in significant linkage disequilibrium with HindIII. The LPL Ser447Stop mutation appears to have a protective effect against the development of atherosclerosis and subsequent atherothrombotic cerebral infarction. Our results suggest that the Ser447Stop mutation of the LPL gene is a novel genetic marker for atherothrombotic cerebral infarction. Further prospective investigations in a large population among various races are required to confirm these findings.
